<DOC>
	<DOCNO>NCT02006485</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness Ublituximab combination TGR-1202 , without ibrutinib bendamustine , patient advance hematologic malignancy</brief_summary>
	<brief_title>Ublituximab Combination With TGR-1202 +/- Ibrutinib Bendamustine Patients With B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Confirmed Bcell nonHodgkin lymphoma ( NHL ) , chronic lymphocytic leukemia ( CLL ) /small lymphocytic lymphoma ( SLL ) , Bcell lymphoproliferative disorder approve Medical Monitor Study Chair Refractory relapse least 1 prior treatment regimen Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Any major surgery , chemotherapy immunotherapy within last 21 day Known hepatitis B virus , hepatitis C virus HIV infection Autologous hematologic stem cell transplant within 3 month study entry Allogeneic hematologic stem cell transplant within 12 month Primary central nervous system lymphoma know intracranial involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>